Recent Updates
Recently added Catalysts
BBIO

BridgeBio Pharma to Participate in November Investor Events

Key Takeaway: PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in
Price reaction · baseline $9.25 (2022-11-08 close) · hit after-hours · clean, no other BBIO news in the window
day 0 close
-8.4%
day 1
+9.9%
day 3 · peak
+16.1%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis

Full Press Release Details

PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences:
Jefferies Health Care Conference, London, UK: November 15th at 9:40 am ET
Evercore ISI HealthCONx Conference, Virtual: November 30th at 10:05 am ET
To access the live webcast of BridgeBio’s presentations, please visit the “Events” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.
About BridgeBio Pharma, Inc.
Last updated: Nov 9, 2022